Literature DB >> 15064712

Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells.

Oliver Riesterer1, Daniel Zingg, Jörg Hummerjohann, Stephan Bodis, Martin Pruschy.   

Abstract

An intact VEGF receptor/PI3K/PKB/Akt signaling cascade protects endothelial cells from apoptotic stress-stimuli and mediates the formation of new blood vessels in pathological conditions such as cancer. Therefore, downregulation of this signaling cascade is of clinical interest for antiangiogenic cancer therapy. In this report, we demonstrate that VEGF controls the protein stability of the serine-threonine kinase PKB/Akt via inhibition of PKB/Akt protein degradation. VEGF deprivation or blockage of the VEGF signal transduction cascade with the VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 resulted in a specific decrease of the PKB/Akt protein level and subsequent cellular restimulation with VEGF rescued its stability. Real-time quantitative RT-PCR analysis demonstrated that VEGF does not regulate PKB/Akt gene expression. On the other hand, broad range inhibitors of caspases and the proteasome complex prevented VEGF-dependent downregulation of the PKB/Akt protein level indicating that PKB/Akt protein stability is regulated by VEGF-controlled proteolysis. Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability. These results demonstrate a novel regulatory mechanism of the activated VEGF receptor/mTOR-signal transduction pathway to control the protein stability of PKB/Akt and survival threshold in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064712     DOI: 10.1038/sj.onc.1207596

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  Akt is negatively regulated by the MULAN E3 ligase.

Authors:  Seunghee Bae; Sun-Yong Kim; Jin Hyuk Jung; Yeongmin Yoon; Hwa Jun Cha; Hyunjin Lee; Karam Kim; Jongran Kim; In-Sook An; Jongdoo Kim; Hong-Duck Um; In-Chul Park; Su-Jae Lee; Seon Young Nam; Young-Woo Jin; Jae Ho Lee; Sungkwan An
Journal:  Cell Res       Date:  2012-03-13       Impact factor: 25.617

2.  ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3.

Authors:  Sonali Ghosh; Moitri Basu; Sib Sankar Roy
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

Review 3.  Degradation of activated protein kinases by ubiquitination.

Authors:  Zhimin Lu; Tony Hunter
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

4.  Bone vascularization and trabecular bone formation are mediated by PKB alpha/Akt1 in a gene-dosage-dependent manner: in vivo and ex vivo MRI.

Authors:  Katrien Vandoorne; Jeremy Magland; Vicki Plaks; Amnon Sharir; Elazar Zelzer; Felix Wehrli; Brian A Hemmings; Alon Harmelin; Michal Neeman
Journal:  Magn Reson Med       Date:  2010-07       Impact factor: 4.668

5.  Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB.

Authors:  Lara F Costa; Mercedes Balcells; Elazer R Edelman; Lee M Nadler; Angelo A Cardoso
Journal:  Blood       Date:  2005-09-01       Impact factor: 22.113

6.  RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma.

Authors:  Sumanta K Pal; Miaoling He; Tommy Tong; Huiqing Wu; Xueli Liu; Clayton Lau; Jin-Hui Wang; Charles Warden; Xiwei Wu; Sabina Signoretti; Toni K Choueiri; Jose A Karam; Jeremy O Jones
Journal:  Mol Cancer Res       Date:  2014-09-02       Impact factor: 5.852

7.  Physiological regulation of Akt activity and stability.

Authors:  Yong Liao; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

8.  Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells.

Authors:  Hana Okhrimenko; Wei Lu; Cunli Xiang; Nathan Hamburger; Gila Kazimirsky; Chaya Brodie
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

Review 9.  The future of tyrosine kinase inhibitors: single agent or combination?

Authors:  Keith T Flaherty
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

10.  Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.

Authors:  Teruaki Fujishita; Koji Aoki; Heidi A Lane; Masahiro Aoki; Makoto M Taketo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.